Clinical Research

The Puzzle Of Antibiotic Innovation

This new post by Kevin Outterson appears on the Health Affairs Blog, as part of part of a series stemming from the Third Annual Health Law Year in P/Review event held at Harvard Law School on Friday, January 30, 2015. Dame Sally Davies, the Chief Medical Officer of England, warns that we are approaching an antibiotic apocalypse. A…

Published:

This new post by Kevin Outterson appears on the Health Affairs Blog, as part of part of a series stemming from the Third Annual Health Law Year in P/Review event held at Harvard Law School on Friday, January 30, 2015.

Dame Sally Davies, the Chief Medical Officer of England, warns that we are approaching an antibiotic apocalypse. A former chief economist at Goldman Sachs estimates that unless dramatic action is taken now, antimicrobial resistance could kill 50 million people a year and cause $100 trillion in cumulative economic damages.

In the US, dire warnings have issued from the Centers for Disease Control and Prevention (CDC), the President’s Council of Advisors on Science and Technology, and the President himself through an Executive Order on Combating Antibiotic-Resistant Bacteria in September 2014 (summary here). The President’s new budget asks for $1.2 billion to be spent on antibiotic resistance. […]

Read the full post here.

 

About the author

  • Kevin Outterson

    Kevin Outterson has served as a guest blogger on Bill of Health. Kevin teaches health law and corporate law at Boston University, where he co-directs the Health Law Program. He serves as Editor-in-Chief of the Journal of Law, Medicine & Ethics; faculty co-advisor to the American Journal of Law & Medicine; immediate past chair of the Section on Law, Medicine & Health Care of the AALS; and a member of the Board of the American Society of Law, Medicine & Ethics. Before teaching, Kevin was a partner at two major US law firms.